Pfizer · NSE: PFIZER · BSE: 500680
Q4 FY23 results · Jan–Mar 2023
Pfizer reported revenue from operations of ₹572.64 crore (up 4.2% from Q4 FY22) and net profit of ₹129.65 crore (up 3.1% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a standalone basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 572.64 | 549.66 | +4.2% | 621.75 | −7.9% |
| Other income | 31.38 | 17.12 | +83.3% | 27.41 | +14.5% |
| Total income | 604.02 | 566.78 | +6.6% | 649.16 | −7.0% |
| Profit before tax | 164.72 | 145.11 | +13.5% | 200.68 | −17.9% |
| Net profit for the period | 129.65 | 125.79 | +3.1% | 150.66 | −13.9% |
| EPS, basic (₹) | 28.34 | 27.50 | not comparable | 32.93 | not comparable |
| Net margin (%) | 22.6 | 22.9 | 24.2 |
Standalone
- Filed with BSE
- 16 May 2023, 11:01 IST
- Board meeting
- 15 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE